Q-ROSUVASTATIN 40.0 MG — DIN 02390558
ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40.0 MG · QD PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is Q-ROSUVASTATIN?
Q-ROSUVASTATIN 40.0 MG contains ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40.0 MG. It is listed in the Health Canada Drug Product Database under DIN 02390558, held by QD PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 21-Aug-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is Q-ROSUVASTATIN used for?
Q-ROSUVASTATIN (rosuvastatin calcium) is indicated as an adjunct to diet for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions, when response to diet and exercise alone has been inadequate. It is also indicated to reduce the risk of nonfatal myocardial infarction, nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rosuvastatin cost around the world?
Rosuvastatin is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 174 | USD███.██ |
| Czechia | max producer price (ex-factory) | 18 | 140 | CZK███.██ |
| Greece | producer price (ex-factory) | 113 | 113 | EUR███.██ |
| Australia | ex-manufacturer | 17 | 88 | AUD███.██ |
| Saudi Arabia | public | 43 | 82 | SAR███.██ |
| South Africa | single exit price | 72 | 80 | ZAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 11 | 74 | SEK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 64 | 64 | EUR███.██ |
| Romania | max producer price | 45 | 55 | RON███.██ |
| Hungary | producer price (ex-factory) | 38 | 49 | HUF███.██ |
| Luxembourg | reimbursement | 32 | 32 | EUR███.██ |
| Bahrain | retail (max) | 2 | 5 | BHD███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
960 pack listings across 463 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Rosuvastatin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Rosuvastatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
29 holders have a Canadian DIN containing Rosuvastatin, across 152 DINs, of which 84 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NORA PHARMA INC | 12 | 4 | NRA-ROSUVASTATIN, NRA-ROSUVASTATIN TABLETS, ROSUVASTATIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 12 | 4 | NOVO-ROSUVASTATIN, NTP-ROSUVASTATIN, TEVA-ROSUVASTATIN | Sourceable in Canada |
| ANGITA PHARMA INC. | 8 | 4 | AG-ROSUVASTATIN, AG-ROSUVASTATIN CALCIUM | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 8 | 4 | JAMP ROSUVASTATIN TABLETS, JAMP-ROSUVASTATIN | Sourceable in Canada |
| MANTRA PHARMA INC | 8 | 4 | M-ROSUVASTATIN | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 8 | 4 | IPG-ROSUVASTATIN, MAR-ROSUVASTATIN | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 8 | 4 | ROSUVASTATIN | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 4 | 4 | ACH-ROSUVASTATIN | Sourceable in Canada |
| ASTRAZENECA CANADA INC | 4 | 4 | CRESTOR - 10MG, CRESTOR - 20MG, CRESTOR - 40MG, CRESTOR - 5MG | Sourceable in Canada |
| AURO PHARMA INC | 4 | 4 | AURO-ROSUVASTATIN | Sourceable in Canada |
| BIOMED PHARMA | 4 | 4 | BIO-ROSUVASTATIN | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 4 | 4 | RIVA-ROSUVASTATIN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40.0 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Rosuvastatin |
|---|---|
| ATC code | C10AA07 |
| AHFS class | 24:06.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02390558 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2390558 |
| Brand name | Q-ROSUVASTATIN |
| Generic / active ingredient | ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40.0 MG |
| Market authorization holder | QD PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | C10AA07 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AA |
| Current status | CANCELLED PRE MARKET |
| Status date | 21-Aug-2015 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Rosuvastatin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
84 of 152 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ROSUVASTATIN | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02438917 |
| ACH-ROSUVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02438941 |
| ACH-ROSUVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02438925 |
| ACH-ROSUVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02438933 |
| AG-ROSUVASTATIN CALCIUM | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02500167 |
| AG-ROSUVASTATIN CALCIUM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02500140 |
| AG-ROSUVASTATIN CALCIUM | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02500132 |
| AG-ROSUVASTATIN CALCIUM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02500159 |
| APO-ROSUVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | 02337991 |
| APO-ROSUVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | 02337983 |
2 · Same class — other molecules in ATC C10AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Atorvastatin | ACH-ATORVASTATIN CALCIUM · AG-ATORVASTATIN · APO-ATORVASTATIN · ATORVASTATIN · +35 more | 216 | 87 | Yes |
| Rosuvastatin | ACH-ROSUVASTATIN · ACT ROSUVASTATIN · AG-ROSUVASTATIN · AG-ROSUVASTATIN CALCIUM · +30 more | 152 | 84 | Yes |
| Simvastatin | ACT SIMVASTATIN · AG-SIMVASTATIN · APO-SIMVASTATIN · AURO-SIMVASTATIN · +34 more | 218 | 60 | Yes |
| Pravastatin | ACH-PRAVASTATIN · ACT PRAVASTATIN · AG-PRAVASTATIN · APO-PRAVASTATIN · +30 more | 126 | 51 | Yes |
| Lovastatin | ACT LOVASTATIN · AVA-LOVASTATIN · DOM-LOVASTATIN · LOVASTATIN · +13 more | 35 | 2 | Yes |
| Fluvastatin | LESCOL 20MG · LESCOL 40MG · LESCOL XL · SANDOZ FLUVASTATIN · +2 more | 8 | 2 | Yes |
| Cerivastatin | BAYCOL · BAYCOL (0.2MG) · BAYCOL (0.3MG) | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AX | Alirocumab · Dextrothyroxine · Evinacumab · Evolocumab · Ezetimibe · +5 more | 48 | 28 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is Q-ROSUVASTATIN called?
The same molecule, Rosuvastatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ROSUVASTATIN MSN | Latin | Czechia |
| ROSUCARD | Latin | Czechia |
| Rosuvastatin Viatris | Latin | Czechia, Sweden |
| CORVAPRO NEO | Latin | Czechia |
| Rosuvastatin Sandoz | Latin | Australia, Sweden |
| ROSUVASTATIN TEVA PHARMA | Latin | Czechia |
| SORVASTA | Latin | Czechia |
| Crestor® | Latin | Sweden |
| Rosuvastatin Glenmark | Latin | Sweden |
| APO-ROSUVASTATIN | Latin | Australia |
| APX-Rosuvastatin | Latin | Australia |
| Blooms Rosuvastatin | Latin | Australia |
| Cavstat | Latin | Australia |
| Crestor | Latin | Australia |
| Rosuvastatin Lupin | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.